Download Global CAR T Cell Therapy Market and Clinical Trials Insight 2022 Report

“Global CAR T Cell Therapy Market and Clinical Trials Insight 2022” report highlights the ongoing clinical and non-clinical advancement in the field of Car T Cell Therapy. As per report findings, the promise of CAR modified T cell therapy derives from its combined immunologic benefits and include the specificity of a targeted antibody, the ability to expand the T cell population and the potential for long term persistence to facilitate the ongoing tumor surveillance. The success in early phase trials, assess the feasibility of evaluating the treatment modality across the multiple centers and in larger patients. Currently, there are 99 CAR T Cell based therapies in clinical pipeline and most of them belong to Phase-I and Phase-I/II clinical trials.

In recent years, researchers have identified the chimeric antigen receptor as a potential target for molecular genetics to insert a new epitopes on the receptor region which allows a degree of control of the immune system. CAR T cell therapy satisfy the need to explore new and efficacious adoptive T cell therapy. The gene transfer technology could efficiently introduce the genes encoding CARs into the immune effector cells. The transferring of engineered T cells provides the specific antigen binding in a non-major histocompatibility complex.

The promise of CAR modified T cell therapy derives from its combined immunologic benefits and include the specificity of a targeted antibody, the ability to expand the T cell population and the potential for long term persistence to facilitate the ongoing tumor surveillance. The success in early phase trials, assess the feasibility of evaluating the treatment modality across the multiple centers and in larger patients.

The first commercial application of CAR T Cell based therapy for the treatment of Mantle- Non-Hodgkin's lymphoma is expected to be available from 2020. The anti-CD19 CAR T cell therapy axicabtagene ciloleucel (KTE-C19) is developed by KITE Pharma in collaboration with National Cancer Institute. Currently this therapy is in preregistration phase.

In future, the advancement of CAR T Cell therapy will be largely driven by academia and will require the support for the expensive early phase clinical trials which promise to cover the way for a new form of targeted, exportable immunotherapy for cancer patient. The manufacturing of CD19 CAR T cell therapy CTL019 is in a way which will modernize the process of using the therapy globally. The anticipation of regulatory and manufacturing issues before they arise and proactively addressing the concerns helps to accelerate the process of bringing this promising therapeutic approach to more patients in future.


“Global CAR T Cell Therapy Market and Clinical Trials Insight 2022” report highlights:

CAR T Cell Therapies Delivery Pipeline and Mechanism of Action
Global CAR T Cell Therapy Clinical Trials for Cancer Treatment
Global CAR T Cell Therapies Clinical Pipeline by Company, Indication and Phase
Global CAR T Cell Therapies Clinical Pipeline: 99 Therapies
CAR T Cell Therapies in Highest Phase: Preregistration
Majority of CAR T Cell Therapies in Phase-I/II Trials: 16 Therapies
Global Market Scenario of CAR T Cell Therapy
Global CAR T Cell Therapy Market Future Prospects

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink: https://www.kuickresearch.com/report-global-car-t-cell-therapy-market-and-clinical-trials-insight-2022.php

1. Chimeric Antigen Receptor (CAR) T Cell Therapy - Next Era in Immuno Oncology
1.1 Overview
1.2 History and Development of CAR-T Technology

2. Evolution of Chimeric Antigen Receptor (CAR) T-Cell Design
2.1 Structure of CAR T Cell
2.2 1nd Generation Chimeric Antigen Receptor
2.3 2nd and 3nd Generation CAR T Cell

3. Principle of Chimeric Antigen Receptor Design
3.1 CAR Modified T Cells: Targeting
3.2 CAR Modified T Cell: Signaling

4. CAR T Cell Therapies Delivery Pipeline and Mechanism of Action
4.1 Process of CAR T Cell Therapy
4.2 Mechanism of Action

5. Approaches to Improve the CAR T Cell Therapy
5.1 Introduction
5.2 Targeting the Tumor Stroma with CAR T Cells
5.3 Targeting the Cytokine Networks
5.4 Combination Strategies for CAR T Cells
5.5 Targeting the Immune Checkpoints

6. Global CAR T Cell Therapy Clinical Trials for Cancer Treatment
6.1 Acute Lymphoblastic Leukemia
6.2 Multiple Myeloma
6.3 Brain Tumors
6.4 Lymphoma
6.5 Solid Tumors

7. Global CAR T Cell Therapies Clinical Pipeline by Company, Indication and Phase
7.1 Research
7.2 Preclinical
7.3 Clinical
7.4 Phase-I
7.5 Phase-I/II
7.6 Phase-II
7.7 Preregistration

8. Global Market Scenario of CAR T Cell Therapy
8.1 Overview
8.2 Estimated Price Analysis of CAR T Cell Therapy

9. Global Market Size of CAR T Cell Therapy
9.1 Market Share of Cancer Immunotherapy by its Technology
9.2 CAR T Cell Therapy Market Value

10. Global CAR T Cell Therapy Market Dynamics
10.1 Favorable Parameters
10.2 Challenges

11. Global CAR T Cell Therapy Market Future Prospects

12. Competitive Landscape
12.1 Autolus
12.2 Bellicum
12.3 Bluebird
12.4 Celgene
12.5 Cellectis
12.6 Celyad
12.7 Eureka Therapeutics
12.8 Fortress Biotech
12.9 Immune Therapeutics
12.10 Juno Therapeutics
12.11 Kite Pharma
12.12 Novartis
12.13 Sorrento therapeutics
12.14 TILT Biotherapeutics
12.15 Ziopharm

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Kuick Research
New Delhi - 110001
India
+91-11-47067990

This release was published on openPR.